Compare Bristol-Myers Squibb Co (BMY) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Unity Software Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.5 (market cap $116.30B), while Unity Software Inc trades at $31.54 (market cap $13.86B). The key difference: Bristol-Myers Squibb Co is far larger — about 8.4× Unity Software Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| BMY | U | |
|---|---|---|
Market Cap | $116.30B | $13.86B |
Sector | Health | Technology |
52-Week High | $62.37 | $49.47 |
52-Week Low | $42.60 | $17.13 |
Enterprise Value | $152.24B | $13.96B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Unity Software (U) trades at $30.68, down 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $36.50. Recent earnings show mixed results, with Q3 2025 beating expectations but subsequent quarters missing, while revenue remains stable around $1.8 billion. The company maintains strong gross margins of 62.79% but reports negative net income margins, reflecting ongoing profitability challenges amid strategic shifts toward AI and advertising.
The outlook for Unity hinges on its AI integration and cost management, offering upside if execution improves, but risks include persistent losses, high debt, and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
